The signs and symptoms that are produced after the acute overdosage of Mepyramine include Convulsions, Coma, Ataxia, Hyperpyrexia, Tremor, Extrapyramidal effects, Excitement.
Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mepyramine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Mepyramine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Mepyramine. |
| Magnesium sulfate | The therapeutic efficacy of Mepyramine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Mepyramine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mepyramine. |
| Mirtazapine | Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Mepyramine. |
| Orphenadrine | Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Mepyramine. |
| Pramipexole | Mepyramine may increase the sedative activities of Pramipexole. |
| Ropinirole | Mepyramine may increase the sedative activities of Ropinirole. |
| Rotigotine | Mepyramine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Mepyramine. |
| Suvorexant | Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Mepyramine. |
| Thalidomide | Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Benzylpenicilloyl polylysine | Mepyramine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Mepyramine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Mepyramine. |
| Sodium oxybate | Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Mepyramine. |
| Ethanol | Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Mepyramine. |
| Sibutramine | The risk or severity of adverse effects can be increased when Mepyramine is combined with Sibutramine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Mepyramine is combined with Zimelidine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Mepyramine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Mepyramine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Mepyramine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Mepyramine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Mepyramine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Mepyramine is combined with Alaproclate. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Mepyramine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Mepyramine is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Mepyramine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Mepyramine is combined with Sertraline. |
| Nefazodone | The risk or severity of adverse effects can be increased when Mepyramine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Mepyramine is combined with Escitalopram. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Mepyramine is combined with Dapoxetine. |
| Amphetamine | Amphetamine may decrease the sedative activities of Mepyramine. |
| Phentermine | Phentermine may decrease the sedative activities of Mepyramine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Mepyramine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Mepyramine. |
| Lisdexamfetamine | The serum concentration of dextroamphetamine, an active metabolite of Lisdexamfetamine, can be increased when used in combination with Mepyramine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Mepyramine. |
| MMDA | MMDA may decrease the sedative activities of Mepyramine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Mepyramine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Mepyramine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mepyramine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Mepyramine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Mepyramine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Mepyramine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Mepyramine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Mepyramine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Mepyramine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Mepyramine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Mepyramine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Mepyramine. |
| Gepefrine | Gepefrine may decrease the sedative activities of Mepyramine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Mepyramine. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Mepyramine. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Mepyramine. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Mepyramine. |
| Gallamine triethiodide | The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Mepyramine. |
| Triflupromazine | The risk or severity of CNS depression can be increased when Triflupromazine is combined with Mepyramine. |
| Lamotrigine | The risk or severity of CNS depression can be increased when Lamotrigine is combined with Mepyramine. |
| Nicardipine | The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Mepyramine. |
| Rocuronium | The risk or severity of CNS depression can be increased when Rocuronium is combined with Mepyramine. |
| Scopolamine | The risk or severity of CNS depression can be increased when Scopolamine is combined with Mepyramine. |
| Clidinium | The risk or severity of CNS depression can be increased when Clidinium is combined with Mepyramine. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Mepyramine. |
| Brompheniramine | The risk or severity of CNS depression can be increased when Brompheniramine is combined with Mepyramine. |
| Doxacurium | The risk or severity of CNS depression can be increased when Doxacurium is combined with Mepyramine. |
| Mivacurium | The risk or severity of CNS depression can be increased when Mivacurium is combined with Mepyramine. |
| Chlorprothixene | The risk or severity of CNS depression can be increased when Chlorprothixene is combined with Mepyramine. |
| Metocurine | The risk or severity of CNS depression can be increased when Metocurine is combined with Mepyramine. |
| Pancuronium | The risk or severity of CNS depression can be increased when Pancuronium is combined with Mepyramine. |
| Pipecuronium | The risk or severity of CNS depression can be increased when Pipecuronium is combined with Mepyramine. |
| Rapacuronium | The risk or severity of CNS depression can be increased when Rapacuronium is combined with Mepyramine. |
| Pizotifen | The risk or severity of CNS depression can be increased when Pizotifen is combined with Mepyramine. |
| Benactyzine | The risk or severity of CNS depression can be increased when Mepyramine is combined with Benactyzine. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Trimebutine. |
| Emepronium | The risk or severity of CNS depression can be increased when Mepyramine is combined with Emepronium. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with Mepyramine. |
| Zopiclone | The risk or severity of adverse effects can be increased when Mepyramine is combined with Zopiclone. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Leuprolide. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Goserelin. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Erythromycin. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Azithromycin. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Moxifloxacin. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Sulfisoxazole. |
| Sulpiride | The risk or severity of CNS depression can be increased when Sulpiride is combined with Mepyramine. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Nimodipine. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mepyramine. |